Role of protein S in castration-resistant prostate cancer-like cells.

Understanding how castration-resistant prostate cancer (CRPC) cells survive the androgen-deprivation condition is crucial for treatment of this advanced prostate cancer (PCa). Here, we reported for the first time the up-regulation of protein S (PROS), an anticoagulant plasma glycoprotein with multiple biological functions, in androgen-insensitive PCa cells and in experimentally induced castration-resistant PCa cells. Overexpression of exogenous PROS in LNCaP cells reduced androgen deprivation-induced apoptosis and enhanced anchorage-dependent clonogenic ability under androgen deprivation condition. Reciprocally, PROS1 knockdown inhibited cell invasiveness and migration, caused the growth inhibition of castration-resistant tumor xenograft under androgen-depleted conditions, and potentiated Taxol (a widely prescribed anti-neoplastic agent)-mediated cell death in PC3 cells. Furthermore, PROS overexpression significantly stimulated AKT activation but failed to evoke oxidative stress in LNCaP cells under normal condition, suggesting that the malignance-promoting effects of the above-mentioned pathway may occur in the order of oxidative stress/PROS/AKT. The potential mechanism may be due to control of oxidative stress-elicited activation of PI3K-AKT-mTOR pathway. Taken together, our gain-of-function, loss-of-function analyses suggest that PROS may facilitate cell proliferation and promote castration resistance in human castration-resistant PCa-like cells via its apoptosis-regulating property. Future study emphasizing on delineating how PROS regulate cellular processes controlling transformation during the development of castration resistance should open new doors for the development of novel therapeutic targets for CRPC.

[1]  H. Miyake,et al.  Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration-resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo. , 2015, Urology.

[2]  M. Gleave,et al.  Targeting the adaptive molecular landscape of castration-resistant prostate cancer , 2015, EMBO molecular medicine.

[3]  W. Figg,et al.  Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. , 2015, Southern medical journal.

[4]  M. Gleave,et al.  Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer , 2015, Oncotarget.

[5]  H. Moch,et al.  Molecular foundations for personalized therapy in prostate cancer. , 2015, Current drug targets.

[6]  Zhe Zhang,et al.  Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. , 2014, Cancer research.

[7]  Wei Li,et al.  A chromatin modifier regulates Sertoli cell response to mono-(2-ethylhexyl) phthalate (MEHP) via tissue inhibitor of metalloproteinase 2 (TIMP2) signaling. , 2014, Biochimica et biophysica acta.

[8]  Yong Li,et al.  PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways , 2014, Cell Death and Disease.

[9]  Ronald C. Chen,et al.  Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Zoubeidi,et al.  Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer , 2014, Oncogenesis.

[11]  L. Adams,et al.  New recommendations in prostate cancer screening and treatment , 2014, JAAPA : official journal of the American Academy of Physician Assistants.

[12]  E. Antonarakis,et al.  Castration-resistant prostate cancer: latest evidence and therapeutic implications , 2014, Therapeutic advances in medical oncology.

[13]  O. Sartor,et al.  Castration-resistant prostate cancer: adaptive responses in the androgen axis. , 2014, Cancer treatment reviews.

[14]  E. Lasorsa,et al.  Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer , 2013, Oncotarget.

[15]  He Wang,et al.  Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC‐3 human prostate cancer cells , 2013, FEBS letters.

[16]  S. Hotte,et al.  Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  Andrew J Armstrong,et al.  Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. , 2013, Endocrine-related cancer.

[18]  G. Espinosa,et al.  Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity , 2013, Arthritis Research & Therapy.

[19]  S. Nilsson,et al.  Somatostatin Derivative (smsDX) Targets Cellular Metabolism in Prostate Cancer Cells after Androgen Deprivation Therapy , 2013, PloS one.

[20]  A. Armstrong,et al.  Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. , 2013, Endocrine-related cancer.

[21]  H. Ho,et al.  Characterization of global metabolic responses of glucose-6-phosphate dehydrogenase-deficient hepatoma cells to diamide-induced oxidative stress. , 2013, Free radical biology & medicine.

[22]  E. Wallen,et al.  A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. , 2013, Urologic oncology.

[23]  Dominique Trudel,et al.  Proteomic Profiling of Androgen-independent Prostate Cancer Cell Lines Reveals a Role for Protein S during the Development of High Grade and Castration-resistant Prostate Cancer , 2012, The Journal of Biological Chemistry.

[24]  Yue Zhang,et al.  Toll‐like receptor‐mediated inhibition of Gas6 and ProS expression facilitates inflammatory cytokine production in mouse macrophages , 2012, Immunology.

[25]  Cora N. Sternberg,et al.  Castration-Resistant Prostate Cancer , 2010, Drugs.

[26]  Seiji Naito,et al.  Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. , 2011, Free radical biology & medicine.

[27]  Bao-xue Yang,et al.  Prostate cancer: an emerging threat to the health of aging men in Asia. , 2011, Asian journal of andrology.

[28]  H. Kung Targeting Tyrosine Kinases and Autophagy in Prostate Cancer , 2010, Hormones & cancer.

[29]  José A Fernández,et al.  Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway , 2011, Molecular Neurodegeneration.

[30]  Ayako Nishimoto,et al.  Establishment and characterization of an androgen receptor‐dependent, androgen‐independent human prostate cancer cell line, LNCaP‐CS10 , 2010, The Prostate.

[31]  Su Qu,et al.  PI3K-AKT-mTOR Pathway is Dominant over Androgen Receptor Signaling in Prostate Cancer Cells , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[32]  José A Fernández,et al.  Species-specific anticoagulant and mitogenic activities of murine protein S , 2009, Haematologica.

[33]  G. Lemke,et al.  Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. , 2009, The Journal of clinical investigation.

[34]  Jie Zhao,et al.  Involvement of Metastasis Tumor Antigen 1 in Hepatic Regeneration and Proliferation , 2008, Cellular Physiology and Biochemistry.

[35]  Wei Li,et al.  Metastasis tumor antigen 1 is involved in the resistance to heat stress‐induced testicular apoptosis , 2008, FEBS letters.

[36]  B. Dahlbäck The tale of protein S and C4b-binding protein, a story of affection , 2007, Thrombosis and Haemostasis.

[37]  N. Caplen,et al.  Defining and assaying RNAi in mammalian cells. , 2005, Molecular cell.

[38]  M. Thakur,et al.  Androgen receptor mRNA is inversely regulated by testosterone and estradiol in adult mouse brain , 2004, Neurobiology of Aging.

[39]  D. Grigoryev,et al.  Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. , 2000, Cancer research.